Business Context and Reporting Period
This Form 8-K Current Report was filed by Marchex, Inc. (MCHX) on January 4, 2021, covering events occurring on December 31, 2020, and January 4, 2021. The filing details the approval of executive compensation plans, including cash bonuses and equity awards, for the 2021 fiscal year.
Key Financial Metrics and Compensation Details
The filing does not report operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. Instead, it discloses specific compensation figures:
- 2021 Target Cash Bonus Pool: $568,438 for initial executive officers (Michael Arends and Russell Horowitz), with a maximum potential payout of 195% of the target.
- Individual Target Bonuses: $250,000 for Chief Revenue Officer John Roswech and $160,000 for Chief Product and Strategy Officer Ryan Polley.
- Equity Grant Exercise Prices: $1.96 per share (December 31, 2020 grant) and $2.02 per share (January 4, 2021 grant).
Material Changes and Equity Awards
The Compensation Committee approved two distinct rounds of equity grants under the 2012 Stock Incentive Plan:
- December 31, 2020 Grant:
- Russell C. Horowitz: 95,000 options and 95,000 restricted shares.
- Michael Arends: 195,000 options and 195,000 restricted shares.
- Vesting: 5-year cliff vesting with acceleration triggers based on revenue, adjusted OIBA, or share price milestones.
- January 4, 2021 Grant:
- Russell C. Horowitz: 41,000 options and 41,000 restricted shares.
- Ryan Polley: 20,000 options and 20,000 restricted shares.
- John Roswech: 35,000 options and 35,000 restricted shares.
- Michael Arends: 46,000 options and 46,000 restricted shares.
- Vesting: 4-year schedule (25% annually or quarterly increments) with acceleration provisions.
Outlook, Risks, and Performance Targets
Compensation is tied to specific performance targets for the 2021 fiscal year, weighted equally (33 1/3% each) across revenue (new and total) and adjusted OIBA. Accelerated vesting for the December 31 grant is contingent on:
- 2021 revenue exceeding 120% of the 2020 level.
- 2021 adjusted OIBA exceeding specified multiples of the 2020 level.
- Share price exceeding 150% of the initial 2020 average for 20 consecutive trading days.
Further acceleration occurs if trailing 12-month revenue exceeds 127% of the 2020 level or share price exceeds 160% of the 2020 average. The filing notes standard "Double-Trigger Change in Control Acceleration" provisions.
Investor Verification Checklist
- Verify the 2020 baseline revenue and adjusted OIBA figures to assess the feasibility of the 120% and 127% growth targets.
- Confirm the total number of shares authorized under the 2012 Stock Incentive Plan to evaluate dilution impact.
- Review the specific definition of "adjusted OIBA" used in the performance metrics.
- Monitor the stock price relative to the $1.96 and $2.02 exercise prices to gauge immediate option value.